

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 November 2023 (30.11.2023)



(10) International Publication Number
WO 2023/229819 A1

(51) International Patent Classification:

C12N 5/02 (2006.01) C12M 3/02 (2006.01)
A61K 35/30 (2015.01) C12N 5/079 (2010.01)
A61P 25/00 (2006.01)

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2023/020916

(22) International Filing Date:

04 May 2023 (04.05.2023)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/345,251 24 May 2022 (24.05.2022) US
63/356,536 29 June 2022 (29.06.2022) US

(71) Applicant: **BLUEROCK THERAPEUTICS LP**

[US/US]; 1 Broadway, Floor 15, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **STARIKOV, Lev**; c/o Bluerock Therapeutics LP, 1 Broadway, Floor 15, Cambridge, Massachusetts 02142 (US).

HSU, Juliana; c/o Bluerock Therapeutics LP, 1 Broadway, Floor 15, Cambridge, Massachusetts 02142 (US). **CUTIA, Thomas**; c/o Bluerock Therapeutics LP, 1 Broadway, Floor 15, Cambridge, Massachusetts 02142 (US). **EBEL, Mark**; c/o Bluerock Therapeutics LP, 1 Broadway, Floor 15, Cambridge, Massachusetts 02142 (US). **TOMISHIMA, Mark**; c/o Bluerock Therapeutics LP, 1 Broadway, Floor 15, Cambridge, Massachusetts 02142 (US).

(74) Agent: **GROLZ, Edward**; Scully, Scott, Murphy & Presser, 400 Garden City Plaza, Suite 300, Garden City, New York 11530 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: METHODS OF MAKING OLIGODENDROCYTE PROGENITOR CELLS

(57) Abstract: The present disclosure is directed to methods of producing oligodendrocyte progenitor cells (OPCs). In addition, methods of treating demyelinating diseases using oligodendrocyte progenitor cells (OPCs) are also disclosed.

